Ardelyx, Inc. (ARDX)
After hours:
| Previous Close | 0.5993 |
| Open | 0.5900 |
| Bid | 0.6001 x 1800 |
| Ask | 0.6101 x 1800 |
| Day's Range | 0.5900 - 0.6290 |
| 52 Week Range | 0.4900 - 8.2470 |
| Volume | |
| Avg. Volume | 3,607,598 |
| Market Cap | 85.53M |
| Beta (5Y Monthly) | 1.85 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3610 |
| Earnings Date | Aug 11, 2022 - Aug 15, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.14 |
- Zacks
Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates
Ardelyx (ARDX) delivered earnings and revenue surprises of -5% and 87.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced the appointment of Muna Bhanji, R.Ph., to its board of directors. “We welcome Muna whose deep expertise in global commercialization and market access will be critical to Intellia as we expand our leadership position in the field of genome editing and move closer
- Zacks
Ardelyx (ARDX) Reports Q4 Loss, Misses Revenue Estimates
Ardelyx (ARDX) delivered earnings and revenue surprises of -24% and 48.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
